Danaher Corporation

Danaher Corporation

DHRยทNYSE

$178.08

-1.0%
HealthcareMedical - Diagnostics & Research

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

At a Glance

Live Snapshot
Market Cap$126.04B
EPS5.0700
P/E Ratio44.80
Earnings Date07/28/2026
dhr

Danaher Corporation Street Expectations Map

DHR ยท NYSE

Wall Street analysts project that DHR stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 238.30, with estimates ranging from a low of 200.00 to a high of 265.00.

Lowest Target
200.00
12.31%
Consensus Target
238.30
33.82%
Highest Target
265.00
48.81%

The consensus 1-year price target stands at 238.30, with estimates ranging from a low of 200.00 to a high of 265.00.

Analyst Consensus Analysis

Upside Potential

+33.8%

Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.

Analyst Agreement

27.3% spread

Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.

Analyst Conviction

Very High

Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.

Market Sentiment Insight

Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.

dhr

Danaher Corporation Forward Estimates of Revenue

DHR ยท NYSE
Latest Revenue
24.57B
FY 2025
Avg Estimate
25.51B
FY 2026
Estimate Range
25.33B - 25.83B
Analyst Spread

Forward Growth Analysis

Projected Growth+3.9%

Flat growth suggests market maturity or near-term challenges offsetting expansion efforts.

Analyst Coverage18 Analysts

Good analyst coverage ensures reliable estimates with diverse professional perspectives.

Estimate Spread2%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

dhr

Danaher Corporation Forward Estimates of Net Income

DHR ยท NYSE
Latest Net Income
3.61B
FY 2025
Avg Estimate
6.23B
FY 2026
Estimate Range
6.15B - 6.31B
Analyst Spread

Forward Growth Analysis

Projected Growth+72.4%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage18 Analysts

Good analyst coverage ensures reliable estimates with diverse professional perspectives.

Estimate Spread3%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

dhr

Danaher Corporation Forward Estimates of EPS

DHR ยท NYSE
Latest EPS
5.07
FY 2025
Avg Estimate
$8.41
FY 2026
Estimate Range
$8.34 - $8.56
Analyst Spread

Forward Growth Analysis

Projected Growth+65.9%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage15 Analysts

Good analyst coverage ensures reliable estimates with diverse professional perspectives.

Estimate Spread3%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

dhr

Danaher Corporation Forward Estimates of EBIT

DHR ยท NYSE
Latest EBIT
4.50B
FY 2025
Avg Estimate
6.05B
FY 2026
Estimate Range
6.01B - 6.12B
Analyst Spread

Forward Growth Analysis

Projected Growth+34.5%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage18 Analysts

Good analyst coverage ensures reliable estimates with diverse professional perspectives.

Estimate Spread2%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

dhr

Danaher Corporation Forward Estimates of EBITDA

DHR ยท NYSE
Latest EBITDA
6.95B
FY 2025
Avg Estimate
8.21B
FY 2026
Estimate Range
8.15B - 8.31B
Analyst Spread

Forward Growth Analysis

Projected Growth+18.2%

Solid growth trajectory indicates healthy business performance and competitive positioning.

Analyst Coverage18 Analysts

Good analyst coverage ensures reliable estimates with diverse professional perspectives.

Estimate Spread2%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Well-supported growth expectations: Strong analyst coverage combined with positive growth projections provides confidence in forward outlook.

dhr

Danaher Corporation Forward Estimates of SG&A Expense

DHR ยท NYSE
Latest SG&A Expense
8.23B
FY 2025
Avg Estimate
7.48B
FY 2026
Estimate Range
7.42B - 7.57B
Analyst Spread

Forward Growth Analysis

Projected Growth-9.2%

Declining expectations indicate headwindsโ€”investigate whether temporary or structural issues.

Analyst Coverage18 Analysts

Good analyst coverage ensures reliable estimates with diverse professional perspectives.

Estimate Spread2%

Narrow estimate range signals strong analyst consensus and predictable business outlook.

OutlookPositive

Generally favorable outlook with reasonable growth prospects and analyst support.

dhr

Danaher Corporation Insider Positioning

DHR ยท NYSE

During the last 12 months, insiders have sold $36.95M worth of DHR shares, with no buying activity reported.

3 Months

Bought

0

0.00

Sold

1.4K

237.21K

Net Activity

-237K

-$237K

3-6 Months

Bought

0

0.00

Sold

1.3K

274.57K

Net Activity

-275K

-$275K

6-9 Months

Bought

0

0.00

Sold

162.5K

35.85M

Net Activity

-35.8M

-$35.85M

9-12 Months

Bought

0

0.00

Sold

2.8K

586.32K

Net Activity

-586K

-$586K

Top Buyers

No buying activity

Top Sellers

1
RMP

Rales Mitchell P

Director, Officer: Chairman Of Exec. Committee

127.4K sharesโ€ข3 transactions

$28.20M

2
MM

Mcgrew Matthew

Officer: Evp & Chief Financial Officer

16.2K sharesโ€ข1 transactions

$3.47M

3
EBW

Ellis Brian W

Officer: Senior Vice President - Gc

14.7K sharesโ€ข1 transactions

$3.22M

4
LT

List Teri

Director

6.1K sharesโ€ข2 transactions

$1.33M

5
MGM

Milosevich Gregory M

Officer: Executive Vice President

1.3K sharesโ€ข1 transactions

$275K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $36.95M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Recent Trend (3 Months)

$237K

Heavy recent selling activity. Recent insider sales notably exceed purchasesโ€”may warrant investigation into company developments.

Insider Participation

High Selling

5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.

Insider Activity Insight

Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.